Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Monte Rosa Therapeutics ( (GLUE) ) just unveiled an announcement.
Monte Rosa Therapeutics has shared promising interim results from its Phase 1/2 study of MRT-2359, a molecular glue degrader targeting MYC-driven solid tumors. The study highlights a favorable safety profile and optimal degradation of GSPT1 at a recommended 0.5 mg daily dosage on a 21 days on, 7 days off schedule. With ongoing safety assessments in combination therapies and strong trial enrollment, the company plans to release further data in Q1 2025, potentially expanding treatment avenues for patients.
Find detailed analytics on GLUE stock on TipRanks’ Stock Analysis page.